Yujiro S. Hata serves as the President and Chief Executive Officer at IDEAYA Biosciences, Inc., a precision medicine oncology company dedicated to the discovery and development of targeted therapeutics. With a robust background in biotechnology and pharmaceuticals, Hata has been instrumental in steering IDEAYA towards its mission of improving patient outcomes through innovative drug development. Before joining IDEAYA, he held significant roles at other prominent biotech companies, showcasing his expertise in strategic planning and corporate growth. Hata's career is marked by his contributions to the biotech industry, particularly in the realm of oncology. He previously served as the Chief Business Officer at Enanta Pharmaceuticals, where he was pivotal in forging strategic partnerships and driving business development initiatives. His tenure at Enanta was characterized by successful collaborations that advanced the company’s pipeline and expanded its market presence. Additionally, Hata's experience at the Broad Institute of MIT and Harvard further honed his skills in drug discovery and development, providing him with a deep understanding of the scientific and commercial aspects of the industry. As President and CEO of IDEAYA Biosciences, Hata leads the company's efforts to bring novel cancer treatments to patients. Under his leadership, IDEAYA has made significant strides in advancing its clinical programs and expanding its research capabilities. Hata's strategic vision and commitment to innovation have positioned IDEAYA as a leader in the field of precision medicine, with a focus on developing therapies that address unmet medical needs. His leadership continues to drive the company forward, fostering a culture of scientific excellence and patient-centricity.